The Significance of Preclinical Evaluation of Sirolimus-, Paclitaxel-, and Zotarolimus-Eluting Stents
- 1 October 2007
- journal article
- review article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 100 (8), S36-S44
- https://doi.org/10.1016/j.amjcard.2007.08.020
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Overview of Pharmacology and Clinical Trials Program with the Zotarolimus‐Eluting Endeavor StentJournal of Interventional Cardiology, 2006
- Pathology of Drug-Eluting Stents in HumansJournal of the American College of Cardiology, 2006
- Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeksEuropean Heart Journal, 2006
- Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting StentsCirculation, 2005
- Relationship between angiographic late loss and target lesion revascularization after coronary stent implantationJournal of the American College of Cardiology, 2005
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Time Course of Stent Endothelialization After Intravascular Radiation Therapy in Rabbit Iliac ArteriesCirculation, 2003
- Drug eluting stents: are human and animal studies comparable?Heart, 2003
- Influence of Topography on Endothelialization of Stents: Clues for New DesignsJournal of Long-Term Effects of Medical Implants, 2000
- Pathobiologic Responses to StentingThe American Journal of Cardiology, 1998